Adenoid Cystic Carcinoma

Preclinical data support future clinical development of ADCs targeting Claudin-6 and NaPi2b Additional presentations include clinical and independent preclinical studies evaluating ADCT-601 targeting AXL LAUSANNE, Switzerland, March 05, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced abstracts on its novel antibody drug conjugates (ADCs) have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting, which will be held in San Diego, CA from April 5-10, 2024. “We’re excited to share compelling preclinical data supporting the future clinical development of the next-generation ADCs in our solid tumor portfolio, including those targeting Claudin-6 and NaPi2b, at the AACR Annual Meeting,” said Mohamed Zaki, MD, PhD, Chief Medical Officer of ADC Therapeutics. “We’re also looking forward to research from independent studies that highlight the potential of another investigational ADC, ADCT-601 targeting AXL.” Details of ADC Therapeutics’ poster presentations are as follows: Title: Preclinical development of a novel camptothecin-based antibody-drug conjugate targeting solid tumors expressing Claudin-6 Abstract: 3122Session Title: Antibody-Drug ConjugatesDate and Time: Monday, April 8, 2024; 1:30 p.m. – 5:00 p.m. PTLocation: Poster Section 21; Board number 3 Title: Preclinical development of NaPi2b-PL2202, a novel camptothecin-based antibody-drug conjugate targeting solid tumors expressing NaPi2b Abstract: 5085Session Title: Novel Immunotherapies and Immune ModulationDate and Time: Tuesday, April 9, 2024; 9:00 a.m. – 12:30 p.m. PTLocation: Poster Section 42; Board number 7 Title: Phase 1b Trial Mipasetamab Uzoptirine (ADCT-601-102) dose escalation in patients with advanced bone and soft tissue sarcomasAbstract: CT059Session Title: Phase I Clinical Trials 1Date and Time: Monday, April 8, 2024; 9:00 a.m. – 12:30 p.m. PTLocation: Poster Section 48; Board number 9 Title: Quantitative systems pharmacology modeling of loncastuximab tesirine combined with mosunetuzumab and glofitamab helps guide dosing for patients with DLBCLAbstract: 875Session Title: Application of Bioinformatics to Cancer Biology 1Date and Time: Sunday, April 7, 2024; 1:30 p.m. – 5:00 p.m. PTLocation: Poster Section 36; Board number 19 Details of an independent poster presentation of an ADCT-601 preclinical study are as follows: Title: Preclinical anti-tumorigenic evaluation of AXL targeting antibody-drug-conjugate in an adenoid cystic carcinoma cell line xenograft modelAbstract: LB022Session Title: Late-Breaking Research: ChemistryDate and Time: Sunday, April 7, 2024; 1:30 p.m. – 5:00 p.m. PTLocation: Poster Section 52; Board number 4 Details of an oral presentation of an NCI-led ADCT-701 study are as follows: Title: Targeting DLK1, a Notch ligand, with an antibody-drug conjugate in adrenocortical carcinomaAbstract: 6573Session Type: MinisymposiumSession Title: Molecular, Preclinical, and Clinical Endocrinology 3Date and Time: Tuesday, April 9, 2024; 3:05 p.m. – 3:20 p.m. PTLocation: TBA About ADC Therapeutics ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. ADC Therapeutics’ CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development. ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on LinkedIn. ZYNLONTA® is a registered trademark of ADC Therapeutics SA. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as “may”, “will”, “should”, “would”, “expect”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “predict”, “potential”, “seem”, “seek”, “future”, “continue”, or “appear” or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: future success and results from the various ADCT development programs presented at AACR, the actual ZYNLONTA® revenue for 4Q 2023, the success of the Company’s updated corporate strategy including operating efficiencies, capital deployment and portfolio prioritization; the Company’s ability to achieve the decrease in total operating expenses for 2023 and 2024, the expected cash runway into 4Q 2025, the effectiveness of the new commercial go-to-market strategy, competition from new technologies, and the Company’s ability to grow ZYNLONTA® revenue in the United States; Swedish Orphan Biovitrum AB (Sobi®) ability to successfully commercialize ZYNLONTA® in the European Economic Area and market acceptance, adequate reimbursement coverage, and future revenue from the same; approval by the NMPA of the BLA for ZYNLONTA® in China submitted by Overland ADCT BioPharma and future revenue from the same, our strategic partners’, including Mitsubishi Tanabe Pharma Corporation, ability to obtain regulatory approval for ZYNLONTA® in foreign jurisdictions, and the timing and amount of future revenue and payments to us from such partnerships; the impact, if any, from data reported by the University of Miami for their IIT in FL; the timing and results of the Company’s or its partners’ clinical trials including LOTIS 5 and 7, ADCT 601 and 602 as well as the Company’s early-stage pipeline research projects, actions by the FDA or foreign regulatory authorities with respect to the Company’s products or product candidates; projected revenue and expenses; the Company’s indebtedness, including Healthcare Royalty Management and Oaktree and Blue Owl facilities, and the restrictions imposed on the Company’s activities by such indebtedness, the ability to repay such indebtedness and the significant cash required to service such indebtedness; and the Company’s ability to obtain financial and other resources for its research, development, clinical, and commercial activities. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the “Risk Factors” section of the Company's Annual Report on Form 20-F and in the Company's other periodic reports and filings with the Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. The Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law. CONTACTS: Investors and MediaNicole RileyADC TherapeuticsNicole.Riley@adctherapeutics.com+1 862-926-9040

SAN MATEO, Calif. and CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that three abstracts have been selected for presentation at the American Association for Cancer Research (AACR) annual meeting, being held from April 5-10, 2024 in San Diego, California. “We are excited to present our data at AACR showing that targeting p300’s enzymatic KAT domain can selectively downregulate IRF4, a long sought after transcription factor dependency in multiple myeloma. Although p300 is an essential gene, our data show that through its relationship as a critical IRF4 cofactor, we can achieve selective antiproliferative effects against myeloma cells,” said Charles Lin, Ph.D., Senior Vice President, Research and Development of Kronos Bio. Details for the AACR 2024 abstracts are as follows: Title: p300 catalytic inhibition selectively targets IRF4 oncogenic activity in multiple myelomaPresenter: Charles Y. Lin, Ph.D., Kronos BioAbstract #: 1691Poster Session: Chromatin Organization and Regulators of Chromatin BiologyLocation: Poster Section 15 Date and Time: Monday, April 8, 2024, from 9:00 a.m. to 12:30 p.m. PT Title: A dose escalation and cohort expansion study of the CDK9 inhibitor KB-0742 in relapsed, refractory and transcriptionally addicted solid tumorsPresenter: Miguel Villalona-Calero, M.D., Citi of Hope National Medical CenterAbstract #: CT158Poster Session: Phase I Clinical Trials in Progress 2Location: Poster Section 50Date and Time: Monday, April 8, 2024, from 1:30 p.m. to 5:00 p.m. PT Title: KB-0742, an oral highly selective CDK9 inhibitor, demonstrates preclinical activity in transcription factor fusion driven adenoid cystic carcinoma patient-derived modelsPresenter: Luis A. Carvajal, Kronos BioAbstract #: 7550Poster Session: Molecular Biology in Clinical Oncology: Characterizing and Modulating Epigenetics and Gene ExpressionLocation: Poster Section 43 Date and Time: Wednesday, April 10, 2024, from 9:00 a.m. to 12:30 p.m. PT About Kronos Bio, Inc.Kronos Bio is a biopharmaceutical company that is advancing an investigational CDK9 inhibitor compound, KB-0742, in clinical trials as a treatment for MYC-amplified solid tumors and other transcriptionally addicted solid tumors as well as a preclinical development candidate, KB-9558, targeting the KAT domain of p300 for multiple myeloma. The Company’s scientific focus is on developing medicines that target deregulated transcription, the hallmark of cancer and other serious diseases. Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass. For more information, visit https://www.kronosbio.com/ or follow the Company on LinkedIn. Company Contact:Margaux BennettVice President, Corporate Development and Investor Relations, Kronos Bio650-781-5026mbennett@kronosbio.com

Immunome will pay $20m upfront and $30m in common stock. A further $37.5m is in line for Ayala if certain milestones are met. Image credit: Shutterstock/PhotobyTawat. Immunome will acquire rights to two clinical assets from oncology company Ayala Pharmaceuticals , in a $50m deal. The deal covers AL102, a Phase III therapy for desmoid tumour treatment, and related compound AL101, currently in Phase II trials for adenoid cystic carcinoma. Immunome will pay $20m upfront and $30m in common stock. Depending on development and commercial milestones, Ayala is also in line to receive a further $37.5m. Though both candidates will transfer hands to Immunome, AL102 is the asset generating the most buzz. The US Food and Drug Administration (FDA) only recently approved the first drug for desmoid tumour treatment, when SpringWorks Therapeutics ’ Ogsiveo (nirogacestat) secured FDA approval in November 2023. Now, Immunome says data from clinical trials shows that AL102 could be more effective than Ogsiveo which, like AL102, is a small molecule gamma secretase inhibitor. See Also: Inmagene to secure licence for two HUTCHMED drug candidates IGC Pharma heads towards a Phase I study for Alzheimer’s disease Results from the Phase II portion of the RINGSIDE study demonstrated an objective response rate of 75% at a dose of 1.2mg AL102. According to the FDA , the objective response rate for Ogsiveo was 41%. There have been no head-to-head studies between the two drugs. AL102’s clinical journey continues in the ongoing Phase III portion of the RINGSIDE study (NCT04871282). The same dose from Phase II is being evaluated in an estimated 192 participants with desmoid tumours. The study’s primary endpoint is progression-free survival after two years. Desmoid tumours are non-cancerous growths that are estimated to affect 1,650 people in the US. They can be found anywhere in the body and are most common in young adults. Due to their aggressive growth in connective tissue, the tumours can cause pain and disability. The disease is currently treated by surgery or radiation, though the tumours can be difficult to remove. Immunome’s CEO Clay Siegall said: “As we complete the work required to advance AL102 to NDA submission, our goal is to bring clinical benefit to an underserved patient population while generating substantial value for stockholders.” Siegall added that the company plans to investigate AL102’s use in more populations of cancer patients. The two candidates from Ayala add to another recent acquisition by Immunome. The company acquired a collection of antibody-related assets from Atreca in a deal worth up to $12m in December 2023.